What we are researching
The purpose of this study is to find out how effective and safe the study medicine is, compared to another active medicine, in helping people, who have excess body weight and type 2 diabetes, lose weight.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT07400107.
Overweight or Obesity
Have a body mass index (BMI) of 27 or higher
Type 2 Diabetes
Have been diagnosed with type 2 diabetes, at least 180 days (about 6 months) before joining the study
Current Treatment
Are currently treating diabetes through lifestyle intervention and/or with a stable dose of oral antidiabetic medicine(s) for at least 90 days before joining the study
Age
18+ years
Study Medicine
2 injections every week
Number of study visits
About 29 visits over a period of about 26 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
Once enrolled, you will be randomly assigned to one of two groups, either the study medicine group or the active comparison medicine. You will receive 2 injections every week. One will be an active medicine (as determined by your group), while the other will be placebo (which has no active medicine in it). All are given as injections under the skin, using an injection pen. Your study team will teach you how to use the injection pen.
Your participation is expected to last about 2 years and 2 months, with a mix of in-person and phone visits every 4 weeks. Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study andfind out whether there is a participating study site near you.
When you call, please reference study 8028 or AMAZE 8
You may also choose to discuss this clinical trial with your healthcare provider.